Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Assess the Safety and Pharmacokinetics of huC242-DM4 Administered as a Single Intravenous Infusion Once Every Three Weeks to Subjects With Solid Tumors

NCT00352131 is registered in ClinicalTrials.gov with ImmunoGen, Inc. as lead sponsor.

NCT NCT00352131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00352131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Assess the Safety and Pharmacokinetics of huC242-DM4 Administered as a Single Intravenous Infusion Once Every Three Weeks to Subjects With Solid Tumors
Lead sponsor
ImmunoGen, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2005
Completion date
December 31, 2009
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-colorectal cancer, pancreatic cancer